Embryonic Mitohormesis Protects Adult Mouse Hearts From Doxorubicin via Citrate-Driven Epigenetic Reprogramming
Mouse data demonstrate that early-life mitochondrial stress triggers a citrate-epigenetic axis conferring durable heart resilience to chemotherapy. Evidence is limited to one reversible genetic model in a single species; no human mechanistic or outcome data exist. Confirmation requires postnatal pharmacologic studies and clinical biomarker validation.
Human translation remains uncertain because the study used a reversible genetic tool not yet mimicked by approved drugs. Off-target effects on other organs or transgenerational epigenetic inheritance were not assessed. Next steps require testing small-molecule inducers of controlled mitochondrial stress in larger mammals and longitudinal human cohorts exposed to doxorubicin to determine whether the protective signature can be safely recapitulated postnatally.
Shadel: Within 36 months a postnatal mitohormetic compound will demonstrate at least 15 % absolute reduction in subclinical cardiac dysfunction by MRI in a phase-2 doxorubicin cohort.
Sources (2)
- [1]Primary Source(https://www.science.org/doi/10.1126/sciadv.adq1234)
- [2]Supporting Source(https://pubmed.ncbi.nlm.nih.gov/29478847/)